COSMOS Pharmaceutical Net Income

The latest net income for CSMYF is $32B as of August 2026. That compares with $31B in the prior-year period — up 3.6% year over year. That is below the sector sector average of $1.7T. Investors often review this figure alongside COSMOS Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSMYF's net income moved from $31B to $32B — a 3.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in COSMOS Pharmaceutical's operating scale or balance-sheet position.

Against its sector companies, CSMYF currently prints $32B for net income, while the sector average sits near $1.7T. That is roughly 98.1% below the sector mean. Large gaps often invite a closer look at COSMOS Pharmaceutical's growth, margins, and balance sheet.

A net income figure of $32B for CSMYF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.7T. Explore the charts below for those layers of context.

After noting CSMYF's net income ($32B), review year-over-year change from $31B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.